HK Stock MarketDetailed Quotes

03933 UNITED LAB

Watchlist
  • 8.960
  • -0.280-3.03%
Market Closed Mar 28 16:08 CST
16.28BMarket Cap5.46P/E (TTM)

About UNITED LAB Company

Federal Pharmaceutical (stock code 03933.HK) was founded in Hong Kong in 1990. It currently has six production entities, including Federal Pharmaceutical Co., Ltd. (Hong Kong), Zhuhai Federal Pharmaceutical Co., Ltd., Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., Guangdong Kaiping Jinyi Capsule Co., Ltd., Federal Pharmaceutical (Inner Mongolia) Co., Ltd., and Inner Mongolia Federal Animal Insurance Pharmaceutical Co., Ltd., a professional chemical and biological product R&D center, with products covering pharmaceutical intermediates, APIs and formulations, with a total of more than 14,000 employees. It is a comprehensive company integrating R&D, production and operation Pharmaceutical Group. All of Federal Pharmaceutical's workshops have passed China's new GMP certification, and several products have successively obtained EU GMP certification and US FDA certification. With advanced enzymatic production technology, Federal Pharmaceutical became the first domestic enterprise to obtain the EU CEP certificate for enzymatic amoxicillin, and many other scientific and technological achievements have obtained national patents. Federal Pharmaceutical currently has 11 series of pharmaceutical products with more than 60 varieties, more than 110 varieties, and a total of 5 series of nearly 50 varieties of APIs and intermediates. Among them, Bundeqing received a national invention patent certificate. It is the first domestic imitation product used to treat moderate to severe Alzheimer's dementia. Antibiotic products such as amoxen, tazoxin, ampicin, etc., have been selling well for many years, and their excellent curative effects and quality have been deeply trusted and praised by users. The group continues to promote consistency evaluation work. Currently, several products such as Federal Amoxen capsules (0.25g), Federal cefoxin tablets (0.25g), and bondeqing memantine hydrochloride tablets (10mg) have passed a consistent evaluation of generic drug quality and efficacy, showing that they are consistent with the original research drug in terms of quality and efficacy, and can replace each other clinically with the original research drug. Federal Pharmaceutical has been committed to biopharmaceutical research for more than ten years, and has invested heavily to establish large-scale human insulin and similar production bases in Zhuhai and Zhongshan, thus integrating industry and research in the field of diabetic biopharmaceuticals. Currently on the market are the insulin injection “Yuslin USLIN”, the glycine insulin injection “Federal Yulelin USLEN”, and the Mendon insulin injection Federal Ublin series. The USLIN and UBLIN series products of Yusilong UBLIN use Pichia yeast expression technology and have the advantages of high purity, good safety, and affordability. The glycine insulin injection “Federal Yulelin USLEN” uses advanced purification technology, and the product quality conforms to the standards of the US Pharmacopeia. Federal Pharmaceuticals is the first company in China to have the capacity to produce second-generation and third-generation insulin at the same time. Federal Pharmaceuticals has advanced production equipment and sufficient production capacity. The current annual production capacity is 1.8 billion capsules, 1 billion tablets, 134 million granules, 86 million bags of suspensions, 20 million bottles of oral solution, 117 million bottles of powder, 37.8 million bottles of ointments, 28 million bottles of freeze-dried powder needles, 24 million eye drops, and about 300 million insulin preparations. Federal Pharmaceuticals insists on putting equal emphasis on development and environmental protection, and follows the path of sustainable development. It has successively invested nearly 2 billion yuan in environmental management, introduced advanced international technology and equipment, equipped professional teams, worked hard to build green productivity, and won a series of honorary titles such as “Excellent Innovative Enterprise in Guangdong Province” and “Environmental Social Responsibility Enterprise”. Since 1998, Federal Pharmaceutical has completed more than 30 foreign donation projects in the fields of education, disaster relief, and social welfare, with a donation amount of nearly 100 million yuan. It has organized employees to participate in public welfare activities such as unpaid blood donation, social volunteering, and social charity many times, reflecting its responsibility and mission as a modern enterprise. As always, Federal Pharmaceutical is adhering to the promise of “making life more valuable” and is committed to promoting the development of China's medical and health care industry and providing more high-quality and efficient pharmaceutical products to the community.

Company Profile

Symbol03933
Company NameUNITED LAB
ISINKYG8813K1085
Listing Date06/15/2007
Issue Price2.75
Shares Offered300.00M share
Founded03/06/2006
RegistrationCayman Islands
ChairmanHaishan Cai
SecretaryYongkang Liang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOther
Registered OfficeCricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
Head Office and Principal Place of Business6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong
Fiscal Year Ends12-31
Employees15000
MarketHong Kong motherboard
Phone(852)26871033
Fax(852)26871031
Emailtulir@tul.com.hk
Business Federal Pharmaceutical International Holdings Co., Ltd. is an investment holding company that is mainly engaged in the sale of intermediates, APIs and pharmaceutical products. The company operates through three business segments. The Intermediates Division is engaged in the business of selling intermediate products. The API Division is engaged in the business of selling APIs. The Pharmaceutical Products Division is engaged in the business of selling antibiotic formulation products, non-antibiotic formulation products, and hollow capsules. The company also manufactures and sells organic fertilizers through its subsidiaries.

Company Executives

  • Name
  • Position
  • Salary
  • Haishan Cai
  • Chairman,Authorized Representative,Executive Director
  • --
  • Yongkang Liang
  • Company Secretary,Finance Director,Executive Director,Authorized Representative,Vice Chairman,Risk Management Committee Member
  • --
  • Shaozhe Cai
  • Risk Management Committee Member,Executive Director
  • --
  • Yuping Fang
  • VP,Executive Director
  • --
  • Xianhong Zou
  • Executive Director
  • --
  • Suyan Zhu
  • Executive Director,VP
  • --
  • Pinwen Zhang
  • Remuneration Committee Chairman,Independent Non-Executive Director,Audit Committee Chairman,Nomination Committee Member,Chairman of the Risk Management Committee
  • --
  • Min Song
  • Risk Management Committee Member,Independent Non-Executive Director,Nomination Committee Chairman,Remuneration Committee Member,Audit Committee Member
  • --
  • Qiushi Fu
  • Audit Committee Member,Nomination Committee Member,Remuneration Committee Member,Independent Non-Executive Director
  • --
  • Shouting Wu
  • Director of the Group's Zhongshan production plant
  • --
  • Bingyang Liu
  • General Manager of Group Guangdong Kaiping Jinyi Capsule Co., Ltd.
  • --
  • Wenyu Zhang
  • General Manager of Group Federal Pharmaceutical (Inner Mongolia) Co., Ltd.
  • --
  • Yubo Han
  • General Manager of Group Zhuhai Federal Pharmaceutical Co., Ltd.
  • --
  • Hongchi Liu
  • General Manager of the Group Inner Mongolia Federal Insurance Pharmaceutical Co., Ltd.
  • --
  • Shunteng Zheng
  • General Manager of Operations of the Group's Intermediates and Raw Materials Sales Department
  • --
  • Min Chen
  • General Manager of the Group's Pharmaceutical Products Sales Department in China
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg